There are several biologic mechanisms whereby coffee might reduce breast cancer risk. Caffeine and caffeic acid, major coffee constituents, have been shown to suppress mammary tumor formation in animal models and to inhibit DNA methylation in human breast cancer cells, respectively. Coffee may also reduce risk through decreasing inflammation and influencing estrogen metabolism. However, epidemiologic studies have been inconsistent and few studies have examined the association by estrogen and progesterone receptor (ER/PR) status. We evaluated coffee intake for its effect on incident breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort, which included 198,404 women aged 50-71 with no history of cancer, who in 1995-1996 completed a questionnaire capturing usual coffee intake over the past year. State cancer registry and mortality index linkage identified 9,915 primary incident breast carcinomas through December 2006; available information on hormone receptor (HR) status identified 2,051 ER1/PR1 and 453 ER2/PR2 cancers. In multivariable proportional hazards models, coffee intake was not associated with breast cancer risk (p-value for trend 5 0.38; relative risk 5 0.98, 95% confidence interval: 0.91-1.07, for four or more cups per day as compared to women who never drank coffee), and results did not vary by body mass index or history of benign breast biopsy (p-value for interaction > 0.10). We found no evidence of a relationship with either caffeinated or decaffeinated coffee. Null findings persisted for risk of both HR-positive and -negative breast cancers. These findings from a large prospective cohort do not support a role of coffee intake in breast carcinogenesis.
Since reports were published in 1979 linking methylxanthines (caffeine, theophylline and theobromine) to benign breast disease, 1, 2 an established marker of increased breast cancer risk, many epidemiologic studies have examined the association between caffeine or caffeinated beverages, such as coffee, and breast cancer risk. A review of epidemiologic studies published from 1990-1999 concluded that there is no appreciable relation between coffee and breast cancer risk. 3 In 2008, the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) concluded that the evidence for an association between coffee and breast cancer risk was inconclusive for both premenopausal and postmenopausal women. 4 However, summary estimates from a meta-analysis of case-control and cohort studies published that same year suggested a weak inverse relationship for the highest compared to the lowest levels of coffee consumption [relative risk (RR) ¼ 0.95, 95% CI ¼ 0.95-1.00]. 5 Subsequently, five additional cohort studies evaluated the association, with conflicting results. [6] [7] [8] [9] [10] Given the widespread consumption of coffee in the United States and the potential for public health impact, the association between coffee intake and breast cancer risk warrants further investigation.
There are several plausible biologic mechanisms whereby coffee intake might reduce breast cancer risk. Caffeic acid and caffeine, both major constituents of coffee, have been shown to inhibit DNA methylation in human breast cancer cells 11 and to inhibit mammary tumorigenesis in a mouse model, 12 respectively. Coffee intake has been inversely associated with circulating markers of inflammation and insulin resistance, 13, 14 both of which may play a role in breast cancer. 15, 16 Finally, coffee has been linked to endogenous estrogens, as an elevated ratio of circulating 2-hydroxyestrone: 16 alpha-hydroxyestrone 17 and reduced levels of circulating estradiol have been observed with coffee intake in some studies. 18, 19 Although there is some evidence to suggest that coffee and/or caffeine may influence breast cancer risk in part through alterations in estrogens and metabolites, relatively few cohort studies have examined the association according to the hormone receptor (HR) status of breast tumors. 6, 8, 10, 20, 21 The largest of these was the Nurses' Health Study (n ¼ 5,272 cases among 85,987 women); while coffee was not related to breast cancer risk overall, intake of caffeinated coffee or tea was inversely associated with risk of HRpositive breast cancer (RR for highest vs. lowest quintile ¼ 0.88; 95% CI ¼ 0.77-1.00; p-value for trend ¼ 0.01). 21 In contrast, the Women's Health Study (n ¼ 1,188 cases among 38,432 women) observed an increased risk of HR-negative breast cancer associated with caffeine consumption (RR for highest vs. lowest quintile ¼ 1.68, 95% CI ¼ 1.02-2.81; pvalue for trend ¼ 0.02), but no association was observed for HR-positive breast cancer (RR ¼ 0.84, 95% CI ¼ 0.67-1.06; p-value for trend ¼ 0.30). 6 Consistent with these findings, which suggest etiologic heterogeneity, a Swedish cohort study (n ¼ 3,034 cases among 64,603 women) recently reported an increased risk of breast cancer among younger women (<49 years) and a decreased risk among older women (>55 years) associated with drinking coffee four or more times per day; 9 although tumors in older women tend to be HR positive, HR status was not reported in the Swedish study. Of the remaining cohort studies to evaluate associations by HR status, coffee was not related to risk of either HR-positive or -negative tumors. 7, 8, 10, 20 The National Institutes of Health (NIH)-AARP cohort has several advantages for studying this association relative to other studies, including the large size necessary to detect a modest association and the availability of extensive information on potential confounding factors, including body mass index (BMI) and alcohol use. In addition, this large cohort allowed us to examine relationships with clinical features of breast tumors including HR status.
Material and Methods

Study population
The NIH-AARP Diet and Health Study design and methodology have been described in detail. 22 The study was initiated in 1995-1996 when a questionnaire was mailed to 3.5 million members of the AARP (formerly known as the American Association of Retired Persons), aged 50-71 years, who resided in one of eight US states (CA, FL, PA, NJ, NC, LA, GA and MI). This baseline questionnaire captured diet history, demographic characteristics, current weight and height, smoking status, physical activity, medical and reproductive history, menopausal status, menopausal hormone therapy (HT), history of breast biopsy and personal and familial history of cancer. A total of 617,119 (17.6%) questionnaires were returned, of which 567,169 were satisfactorily completed and 179 duplicate questionnaires were excluded.
After additionally excluding individuals who died (n ¼ 261) or moved out of the cancer registry ascertainment area (n ¼ 321) before their baseline questionnaire was received and scanned, proxy respondents to the baseline questionnaire (n ¼ 15,760), six individuals who withdrew from the study, and 325,174 men, the baseline study population included 225,468 women. The study was approved by the Special Studies Institutional Review Board of the US National Cancer Institute, and written informed consent was obtained from study participants.
Analytic sample
We excluded 23,957 women with a personal cancer history other than nonmelanoma skin cancer, 1,848 women with Box-Cox log transformed total energy intake more than two interquartile ranges from the median, 1,231 women who were missing information on coffee intake, nine women who died on the first day of follow-up and 19 women with nonepithelial breast tumors. Thus, 198,404 women were included in the present analysis.
Assessment of coffee intake
Usual coffee intake over the past year was assessed as part of a 124-item food frequency questionnaire. 23 Participants could choose from ten frequency categories: none, less than one cup per month, one to three cups per month, one to two cups per week, three to four cups per week, five to six cups per week, one cup per day, two to three cups per day, four to five cups per day and six or more cups per day. For the present analysis, we collapsed responses into seven groups: never, less than or equal to two cups per week, three to six cups per week, one cup per day, two to three cups per day and four or more cups per day. Participants were also asked whether they drank caffeinated or decaffeinated coffee more than half of the time.
Cohort follow-up
Cohort members were followed periodically for address changes and vital status. Address changes were identified by matching the cohort database to the US Postal Service's National Change of Address database. Vital status was updated through linkage to the US Social Security Administration Death Master File and the National Death Index (NDI) Plus.
Ascertainment of breast cancer
Incident in situ and invasive breast cancers were identified through linkage to the eight cancer registries corresponding to participants' baseline state of residence, as well as Texas and Arizona, in order to capture cancers occurring in participants who moved to these states during follow-up. Each registry has been certified by the North American Association of Central Cancer Registries for meeting the highest 24 A previous validation study in this cohort estimated that registry linkage validly identified $ 90% of all incident cancers. 25 Date of death for fatal cancers (n ¼ 64) was identified through linkage to the NDI.
Statistical analysis
Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals (CI) for breast cancer associated with coffee intake; age was the time scale 26 and ties were handled by enumeration. 27 Follow-up began at the age at which the baseline questionnaire was received and scanned (1995) (1996) and continued through the earliest of the following dates: participant diagnosed with breast cancer, moved out of her registry catchment area, died from any cause, or December 31, 2006. To test the proportional hazards assumption, we generated time-dependent covariates by including an interaction term for coffee intake and the natural log of age (the time metric); probability values were >0.05, consistent with proportional hazards.
Multivariable models were used to control for age at entry (years), race/ethnicity (white black, other/unknown), education (<high school, high school graduate, post high school/ some college, college graduate, post graduate, unknown), BMI (kg/m 2 : <20, 20-22.4, 22.5-24.9, 25-27.4, 27.5-29.9, 30-31.9, 32-33.9, 34þ, unknown), smoking status and dose (nonsmoker, quit and 20 cigarettes per day, quit and >20 cigarettes per day, current smoker and 20 cigarettes per day, current smoker and >20 cigarettes per day, unknown), alcohol (g/day: 0, >0-5, >5-10, >10-20, >20-35, >35), proportion of total energy from fat (quintiles), age at first live birth (nulliparous, <20, 20-24, 25-29, 30þ, unknown), menopausal HT use (never, former, current, unknown), history of breast biopsy (no, yes, unknown) and family history of breast cancer in a first degree relative (no, yes, unknown). In subsequent models, we adjusted for birth year and several additional factors, including ages at menarche and menopause, parity, self-rated health quality, vigorous physical activity and history of diabetes; results were essentially the same and are not shown here. Tests for linear trends across categories of coffee intake were calculated by using an ordinal variable containing the median value of coffee intake (cups per day) within the defined coffee categories.
We used a likelihood ratio test, comparing models with and without the interaction terms, to separately examine effect modification by BMI (<25, 25-<30, !30 kg/m 2 ), HT use (never, ever), smoking status (never, ever), alcohol (g/day: 0, >0-5, >5-10, >10-20, >20-35, >35), history of breast biopsy (never, ever) and family history of breast cancer (no, yes). In addition, we examined whether the relationship between coffee intake and breast cancer incidence differed by ER/PR status, stage at diagnosis (in situ or invasive disease), tumor grade (1, 2, 3þ) and histologic type (ductal, lobular or mixed). To test for heterogeneity in associations between coffee intake and breast cancer subtypes, we conducted caseonly analyses using polytomous logistic regression models adjusting for the same covariates included in our multivariable proportional hazards models as well as age at diagnosis in order to account for duration in the cohort.
Probability values of <0.05 were considered statistically significant. All tests of statistical significance were two-tailed. Analyses were performed using SAS software release 9.1.3 (SAS Institute, Cary, NC).
Results
The mean (standard deviation) age at baseline was 61.8 (5.4) years, and over 96% of women were postmenopausal. The 198,404 women accrued 1,906,185 person years during an average follow-up of 5.2 years (cases) and 9.8 years (noncases). Of the 9,915 women who developed breast carcinoma during follow-up, 1,892 tumors were in situ, 7,959 were invasive and 64 were missing stage. Among the 7,959 invasive breast cancer cases, 5,139 cases were ascertained from state cancer registries reporting HR status; 2,051 were coded as ERþ/ PRþ, 425 as ERþ/PRÀ, 55 as ERÀ/PRþ, 453 as ERÀ/PRÀ, 24 as borderline and 2,131 (41%) were missing either ER or PR status. The majority of invasive breast cancers were ductal carcinomas (n ¼ 5,495), followed by lobular (n ¼ 869), and mixed (n ¼ 680) histologic types; 915 cases had other histologies. Breast cancer risk factors in this population were generally consistent with established associations with age, race/ ethnicity, BMI, ages at menarche, first birth and menopause, parity, menopausal HT use, vigorous physical activity, number of breast biopsies and family history of breast cancer (data not shown).
The vast majority of women (87.9%) reported drinking coffee over the last 12 months. Among all women, 11.0% drank two cups per week or less, 6.8% drank three to six cups per week, 18.3% drank one cup per day, 39.0% drank two to three cups per day and 12.8% drank four or more cups per day. Among women reporting drinking decaffeinated or caffeine-containing coffee (n ¼ 166,788), the majority (63%) drank caffeinated coffee more than half of the time. Compared to never coffee drinkers, women who more frequently drank coffee were more likely to be white, have a lower BMI, smoke and drink alcohol (Table 1) . More frequent coffee drinkers were also less likely to report fair/poor overall health status and a history of diabetes. Similar relationships were observed between these factors with both decaffeinated and caffeinated coffee consumption (data not shown). ), smoking status and dose, alcohol, proportion of total energy from fat (quintiles), age at first live birth, menopausal hormone therapy use, history of breast biopsy and family history of breast cancer. The referent category is never coffee drinkers. p-value for heterogeneity obtained through multivariable polytomous logistic regression models where the referent category is ERþ/PRþ, invasive, grade 1 and ductal histology, respectively. Abbreviations: ER: estrogen receptor; PR: progesterone receptor.
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Coffee intake and breast cancer
Associations between coffee intake and risk of breast cancer, overall and according to clinical characteristics of tumors, are shown in Table 2 . In both age-and multivariable-adjusted proportional hazards models, coffee intake was not associated with breast cancer risk; compared to never coffee drinkers, the multivariable RR for women who reported drinking four or more cups per day was 0.98 (95% CI ¼ 0.91-1.07). In addition, no statistically significant trend was observed with increasing frequency of coffee consumption (p-value for trend ¼ 0.38). The risk associated with coffee intake did not vary substantially by other factors including BMI, HT use, smoking status, alcohol, history of breast biopsy and family history of breast cancer (p-value for interaction > 0.10, data not shown). We further examined associations by ER/PR status, tumor stage, grade and histology. Although slight increases in risk were observed for a few subgroups of women (i.e., for ERþ/ PRþ breast cancer among women who reported drinking three to six cups per week and for grade 2 and lobular tumors among women who reported drinking two cups or less per week), no clear patterns emerged in the relationships between coffee intake and risk for any of the tumor characteristics.
Because recent cohort studies have reported different risk relationships by HR status and caffeine intake, we also explored relationships between caffeinated and decaffeinated coffee consumption with overall breast cancer risk as well as with risk of tumors defined by ER/PR status (Table 3) . Again, coffee showed no association with breast cancer among drinkers of either predominantly caffeinated or predominantly decaffeinated coffee. Compared to never drinkers, the RRs for drinking four or more cups per day of caffeinated and decaffeinated coffee were 0.98 (95% CI ¼ 0.90-1.08) and 1.00 (95% CI ¼ 0.88-1.15), respectively. Risks associated with tumors defined by ER/ PR status also did not vary in any systematic way according to caffeinated versus decaffeinated coffee consumption. In sensitivity analyses, we also restricted analyses to postmenopausal women. Results were similar and are not shown here.
Discussion
In our large prospective study of mostly white, postmenopausal women, coffee intake was not associated with breast cancer risk. This null relationship persisted across tumors with distinct clinical characteristics including ER/PR status, stage, grade and histology. Similarly, no association was observed for either caffeinated or decaffeinated coffee intake.
Our study of 198,404 women is one of the largest cohorts to date to have evaluated the association between coffee intake and breast cancer risk. The study sample size achieved 80% power to minimally detect a reduced risk of 0.92 or an increased risk of 1.09 for those drinking four or more cups per day relative to never coffee drinkers; our observed RR of 0.98 had a corresponding 95% CI of 0.91-1.07, which includes the point estimate of 0.92 but excludes that of 1.09. Thus, it remains possible that we may have failed to detect a very weak association with coffee intake. However, the null finding we observed in our study is consistent with that observed in a recent meta-analysis of nine cohort studies (0.95, 95% CI ¼ 0.88-1.02). 5 The lack of a dose response relationship in our current study lends further support to the evidence that coffee intake does not influence breast cancer risk.
Several previous cohorts observed associations among specific subgroups, such as lean 28 and postmenopausal women, 9, 21 or among women with benign breast disease. 6 However, our study did not replicate these findings nor have the findings from other cohorts. 6, 8, 10, 20, 21 Although there are epidemiologic data to suggest that coffee and/or caffeine may influence estrogen metabolism, [17] [18] [19] none of the six previous cohorts to evaluate associations by HR status found associations with coffee intake; 6, 8, 10, 20, 21 however, with caffeine, one study found decreased risk of ERþ/PRþ tumors 21 whereas a second study found increased risk of ERÀ/PRÀ tumors. 6 We observed no association between coffee and breast cancer, regardless of tumor HR status or coffee caffeine content.
Limitations of our study include the inexactness of the caffeine assessment, which may have reduced our ability to detect distinct associations for caffeinated and decaffeinated coffee. While we did not collect information on the coffee brewing method, in a recent report from a large Swedish cohort, there was some indication that associations with breast cancer risk differed between filtered and boiled coffee, 9 suggesting avenues for future research. In addition, we lacked data on the clinical characteristics of tumors for a substantial proportion of our cases. Nevertheless, due to the large size of our cohort, our analyses of coffee intake and incident ERþ/ PRþ and ERÀ/PRÀ tumors are among the largest to date. Furthermore, the proportions of HR-positive and -negative tumors in our cohort are consistent with those among US women of comparable ages at diagnosis. 29 Despite these limitations, the large size of the NIH-AARP Diet and Health Study allowed for a wide range of coffee intake, and the most common category of intake (i.e., two to three cups per day) is consistent with that observed in other US cohorts of women. 6, 21 Although the proportion of women in our study who drank at least four cups per day is somewhat lower than that reported in other populations, 6 ,21 the actual number of cases occurring in heavy coffee drinkers and the corresponding power is larger than in previous studies.
In conclusion, coffee intake was not associated with breast cancer risk in this large, mostly postmenopausal cohort. Although there are several plausible biologic pathways whereby coffee might influence breast cancer risk, none of them seemed to have affected breast cancer risk in this population. Our findings are consistent with a growing body of literature from prospective cohort studies suggesting that coffee intake is not related to overall breast cancer risk.
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